These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30763190)

  • 21. The pricing of statins and implications for Pharmaceutical Benefits Scheme expenditure.
    Clarke PM
    Med J Aust; 2013 Mar; 198(5):260. PubMed ID: 23496399
    [No Abstract]   [Full Text] [Related]  

  • 22. Four-dollar generics--increased accessibility, impaired quality assurance.
    Choudhry NK; Shrank WH
    N Engl J Med; 2010 Nov; 363(20):1885-7. PubMed ID: 21067379
    [No Abstract]   [Full Text] [Related]  

  • 23. Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents.
    Mattingly Ii TJ; Heil EL; Hoke KS
    J Health Care Poor Underserved; 2017; 28(2):621-625. PubMed ID: 28529212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tailoring access to high cost, genetically targeted drugs.
    Hall WD; Ward R; Liauw WS; Lu CY; Brien JA
    Med J Aust; 2005 Jun; 182(12):607-8. PubMed ID: 15963014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmaceuticals and Medical Devices: Medicare Part D.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2016 Dec; 2016():1-31. PubMed ID: 28252885
    [No Abstract]   [Full Text] [Related]  

  • 26. Drug policy down under: Australia's pharmaceutical benefits scheme.
    Duckett SJ
    Health Care Financ Rev; 2004; 25(3):55-67. PubMed ID: 15229996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oseltamivir becomes plentiful--but still not cheap.
    Enserink M
    Science; 2006 Apr; 312(5772):382-3. PubMed ID: 16627733
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmaceuticals and Medical Devices: Cost Savings.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2015 Dec; ():1-31. PubMed ID: 27116794
    [No Abstract]   [Full Text] [Related]  

  • 29. Pathways to ensure universal and affordable access to hepatitis C treatment.
    Douglass CH; Pedrana A; Lazarus JV; 't Hoen EFM; Hammad R; Leite RB; Hill A; Hellard M
    BMC Med; 2018 Oct; 16(1):175. PubMed ID: 30296935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

  • 31. Hepatitis C virus infection: accessing drug treatment.
    Smyth D; Webster D
    CMAJ; 2015 Oct; 187(15):1113-1114. PubMed ID: 26303249
    [No Abstract]   [Full Text] [Related]  

  • 32. A path to eradication of hepatitis C in low- and middle-income countries.
    Graham CS; Swan T
    Antiviral Res; 2015 Jul; 119():89-96. PubMed ID: 25615583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C drugs not reaching poor.
    Callaway E
    Nature; 2014 Apr; 508(7496):295-6. PubMed ID: 24740042
    [No Abstract]   [Full Text] [Related]  

  • 34. Public procurement of hepatitis C medicines in Brazil from 2005 to 2015.
    Chaves GC; Castro CGSO; Oliveira MA
    Cien Saude Colet; 2017 Aug; 22(8):2527-2538. PubMed ID: 28793069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Moral Distress with Obstacles to Hepatitis C Treatment: A Council of Academic Family Medicine Educational Research Alliance (CERA) Study of Family Medicine Program Directors.
    Simha A; Maria Webb C; Prasad R; Kolb NR; Veldkamp PJ
    J Am Board Fam Med; 2018; 31(2):286-291. PubMed ID: 29535247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. India: access to affordable drugs and the right to health.
    Grover A; Citro B
    Lancet; 2011 Mar; 377(9770):976-7. PubMed ID: 21227487
    [No Abstract]   [Full Text] [Related]  

  • 38. Out-of-pocket costs to users: medicine options for hypertension.
    Arredondo A
    Am J Hypertens; 2008 May; 21(5):492. PubMed ID: 18437138
    [No Abstract]   [Full Text] [Related]  

  • 39. Does patient cost sharing for HCV drugs make sense?
    Lakdawalla DN; Linthicum MT; Vanderpuye-Orgle J
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP188-90. PubMed ID: 27266947
    [No Abstract]   [Full Text] [Related]  

  • 40. A way out of the dismal arithmetic of hepatitis C treatment.
    Bhattacharya J
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP183-4. PubMed ID: 27266945
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.